| Chronic Lymphocytic Leukemia |
1 |
1 |
| Immunoglobulin A (IgA) |
0 |
0.7 |
| Otolaryngology |
0 |
0.53 |
| Biologic Therapy |
0 |
0.51 |
| Intravenous Immunoglobulin (IVIG) |
0 |
0.46 |
| Cancer |
0 |
0.42 |
| Targeted Cancer Therapy |
0 |
0.39 |
| Hypogammaglobulinemia |
0 |
0.37 |
| Cancer Risk |
0 |
0.33 |
| Antibiotics |
0 |
0.28 |
| Immunization |
0 |
0.28 |
| CAR-T |
0 |
0.13 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.12 |
| Antimicrobial Resistance |
0 |
0.1 |
| B-Cell Lymphoma |
0 |
0.99 |
| Blood |
0 |
0.09 |
| Bronchitis |
0 |
0.09 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Lymphoma |
0 |
0.09 |
| Meta-Analysis |
0 |
0.09 |
| Microbicides |
0 |
0.09 |
| Opportunistic Infection |
0 |
0.09 |
| Quality of Life |
0 |
0.09 |
| Multiple Myeloma |
0 |
0.08 |
| Varicella-Zoster Virus |
0 |
0.08 |